-
Earnings Preview For Immucor (BLUD)
Wednesday, April 6, 2011 - 8:53am | 227Immucor Inc. (NASDAQ: BLUD) will be reporting 2011 fiscal third-quarter earnings after the bell today. The consensus estimate for the quarter calls for a profit of $0.27 per share on sales of $79.73 million. The company earned $0.28 cents in the same period a year ago. Earnings estimates have...
-
Piper Jaffray Lowers BLUD Estimates
Wednesday, April 6, 2011 - 7:29am | 175Piper Jaffray is lowering its numbers on Immucor Inc. (NASDAQ: BLUD) in front of 3Q11. “We are updating our forward estimates for currency (which adds $700k to our forward estimate), which is more than offset by our now lower pricing and volume expectations,” Piper Jaffray writes. “Our new $80.5M...
-
Oppenheimer Surveys Non-Profit Hospitals' 1Q11
Wednesday, April 6, 2011 - 7:25am | 203Oppenheimer surveyed 50 non-profit CEOs and CFOs to evaluate capital spending and pricing and volume trends as they relate to major medical device markets. In the report, Oppenheimer writes, “As we saw in our 2Q-4Q10 surveys, our respondents' hospitals continue to see a gradually healing capital...
-
US Stock Futures Up As Investors Await Monsanto Earnings, Gold Futures Hit New High, American Superconductor Shares Drop In Pre-Market Trading
Wednesday, April 6, 2011 - 6:20am | 472US stock futures are higher this morning, as investors are awaiting quarterly results from Monsanto Co (NYSE: MON). Gold futures surged to a new high. Futures for the Dow Jones Industrial Average surged 44 points to 12,371.00, while those for the S&P 500 index rose 5.40 points to 1,332.10....
-
Earnings Scheduled For April 6 (MON, WDFC, BLUD, RT, BBBY, APOG, MSM, RELL, SMSC)
Wednesday, April 6, 2011 - 1:43am | 247Monsanto Company (NYSE: MON) is projected to report its FQ2 EPS at $1.85 on revenue of $4.15 billion. WD-40 Co (NASDAQ: WDFC) is projected to report its FQ2 earnings at $0.67 per share on revenue of $86.67 million. Immucor Inc (NASDAQ: BLUD) is expected to post its FQ3 earnings at $0.27 per...
-
Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest EPS Estimates (DBD, NEOG, VIVO, ABAX)
Wednesday, April 6, 2011 - 1:42am | 147Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of earnings estimate for the next year. The earnings estimate for Immucor Inc (NASDAQ: BLUD) for the next year ending May, 2012 is $1.23 per share. BLUD's trailing-twelve-month operating margin is 39.07...
-
Stocks To Watch For April 6 (BBBY, AMSC, MON, CEPH, VRX, BLUD)
Wednesday, April 6, 2011 - 12:08am | 320Some of the stocks that may grab investor focus today are: Wall Street expects Bed Bath & Beyond Inc (NASDAQ: BBBY) to report its FQ4 EPS at $0.97 on revenue of $2.39 billion. BBBY shares gained 0.96% to $49.37 in after-hours trading. American Superconductor Corp (NASDAQ: AMSC) projects a...
-
Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation Delivered Using the Urgent PC Neuromodulation System
Tuesday, April 5, 2011 - 7:33am | 66Uroplasty, Inc. (NASDAQ: UPI) today announced that two private insurance payers have elected to cover posterior tibial nerve stimulation using its Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms. Effective April 1, 2011, UnitedHealthcare, a...
-
Studies Presented at the SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE Contributes to Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections
Monday, April 4, 2011 - 12:46pm | 122ICU Medical, Inc. (NASDAQ: ICUI) today announced that three different clinical studies presented at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America April 1-4 in Dallas showed that the MicroCLAVE neutral displacement needleless connector helps significantly reduce...
-
Neogen Corporation Up 6% On Upgrade (NEOG)
Thursday, March 31, 2011 - 3:19pm | 67Neogen Corporation (NASDAQ: NEOG) shares are skyrocketing today, gaining more than 6% after the company was upgraded by Hilliard Lyons. Shares were upgraded from Underperform to Neutral. At last check, shares were up $2.56 to $41.86, a gain of 6.5%. Neogen Corporation, through its subsidiaries,...
-
Stephen O'Neil Upgrades NEOG From UP To Neutral
Thursday, March 31, 2011 - 1:05pm | 26According to Bloomberg, Stephen O'Neil (of Hilliard Lyons) has upgraded Neogen Corp. (NASDAQ: NEOG) from Underperform to Neutral.
-
Wedbush Initiates TSON With Outperform
Thursday, March 31, 2011 - 6:16am | 49Analysts at Wedbush initiate coverage of TranS1 Inc (NASDAQ: TSON) with an “outperform” rating. The target price for TSON is set to $7. TSON shares rose 0.50% to close at $4.05 yesterday. More Analyst Ratings here
-
Mad Money Lightning Round OT: Cramer Likes NEOG And ARIA
Wednesday, March 30, 2011 - 7:16pm | 103On CNBC's Mad Money Lightning Round OT, Jim Cramer said that Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) is a good speculative play. Ariad Pharmaceuticals, Inc. (ARIA) gained 1.20% today, and closed at $7.58. Neogen Corporation (NASDAQ: NEOG) sounds speculative, but it isn't, because it is about...
-
Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
Wednesday, March 30, 2011 - 2:55pm | 74Rochester Medical Corporation (Nasdaq: ROCM) announced that the shareholders of Fornix BioSciences N.V. today approved the previously announced sale of Laprolan B.V. its Medical Supplies Division and wholly owned subsidiary to Rochester Medical Corporation. Rochester Medical expects the...
-
J.P. Morgan Reports PG And TEVA Announce A JV
Friday, March 25, 2011 - 7:44am | 166J.P. Morgan has issued a report on the announced JV between Procter & Gamble (NYSE: PG) and Teva Pharmaceutical Industries (NASDAQ: TEVA). According to the report, "Procter has often talked about its desire to grow the OTC platform and partnering with outside companies to improve product...